Repurposing of HDAC inhibitors toward anti-hepatitis C virus drug discovery: Teaching an old dog new tricks

Future Medicinal Chemistry

Volumn 7, Issue 11, 2015, Pages 1367-1371

  Zhao, Fabao ^a   Liu, Na ^a   Zhan, Peng ^a   Liu, Xinyong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

cheminformatics; direct acting antiviral drugs; drug repurposing; hepatitis C virus; histone deacetylase inhibitors; host cellular factors; hydroxamic acids

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; ANTIVIRUS AGENT; HYDROXAMIC ACID;

ANTIVIRAL ACTIVITY; DRUG REPOSITIONING; DRUG TARGETING; HEPATITIS C; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HEPACIVIRUS; PROCEDURES;

ANTIVIRAL AGENTS; DRUG DISCOVERY; DRUG REPOSITIONING; HEPACIVIRUS; HEPATITIS C; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS;

EID: 84938517033     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.76     Document Type: Review

References (25)

1. Hézode C, Asselah T, Reddy KR et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 385(9986), 2502-2509 (2015).
2. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370 (16), 1483-1493 (2014).
3. Shirakawa K, Chavez L, Hakre S, Calvanese V, Verdin E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol. 21(6), 277-285 (2013).
4. Xing S, Siliciano RF. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov. Today 18(11-12), 541-551 (2013).
5. Siliciano JD, Siliciano R F. Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. J. Allergy Clin. Immun. 134(1), 12-19 (2014).
6. Bruner KM, Hosmane NN, Siliciano RF. Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol. 23(4), 192-203 (2015).
7. Lusic M, Giacca M. Regulation of HIV-1 latency by chromatin structure and nuclear architecture. J. Mol. Biol. 427(3), 688-694 (2015).
8. Campbell GR, Bruckman RS, Chu YL, Spector SA. Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1. J. Biol. Chem. 290(8), 5028-5040 (2015).
9. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 48(5), 1420-1429 (2008).
10. Liu H, Trinh TL, Dong H, Keith R, Nelson D, Liu C. Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus. PLoS ONE 7(10), e46631 (2012).
11. Horl WH, Schmidt A. Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C. Nephrol. Dial. Transpl. 29 (6), 1141-1144 (2014).
12. López-Rodríguez R, Hernández-Bartolomé Á, Borque MJ et al. Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy. Genes Immun. 14(5), 317-324 (2013).
13. Sato A, Saito Y, Sugiyama K et al. Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication. J. Cell. Biochem. 114 (9), 1987-1996 (2013).
14. Kozlov MV, Kleymenova AA, Romanova LI et al. Benzohydroxamic acids as potent and selective anti-HCV agents. Bioorg. Med. Chem. Lett. 23(21), 5936-5940 (2013).
15. Kozlov MV, Kleymenova AA, Konduktorov KA, Malikova AZ, Kochetkov SN. Selective inhibitor of histone deacetylase 6 (tubastatin A) suppresses proliferation of hepatitis C virus replicon in culture of human hepatocytes. Biochemistry (Mosc.) 79(7), 637-642 (2014).
16. Kozlov MV, Kleymenova AA, Romanova LI et al. Pyridine hydroxamic acids are specifc anti-HCV agents affecting HDAC6. Bioorg. Med. Chem. Lett. 25(11), 2382-2385 (2015).
17. Kovacs JJ, Murphy PJM, Gaillard S et al. HDAC6 Regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18(5), 601-607 (2005).
18. Parmigiani RB, Xu WS, Venta-Perez G et al. HDAC6 is a specifc deacetylase of peroxiredoxins and is involved in redox regulation. Proc. Natl Acad. Sci. USA 105(28), 9633-9638 (2008).
19. Ai T, Xu Y, Qiu L, Geraghty RJ, Chen L. Hydroxamic acids block replication of hepatitis C virus. J. Med. Chem. 58(2), 785-800 (2015).
20. Song Y, Chen W, Kang D et al. "Old friends in new guise": exploiting privileged structures for scaffold re-evolution/refning. Comb. Chem. High Throughput Screen. 17(6), 536-553 (2014).
21. Li X, Zhan P, Liu H et al. Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. Bioorg. Med. Chem. 20 (18), 5527-5536 (2012).
22. Song Y, Lin X, Kang D et al. Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate. Eur. J. Med. Chem. 82, 293-307 (2014).
23. Raju TN. The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98). Lancet 355, 1022 (2000).
24. Song Y, Zhan P, Liu X. Heterocycle-thioacetic acid motif: a privileged molecular scaffold with potent, broad-ranging pharmacological activities. Curr. Pharm. Design 19 (40), 7141-7154 (2013).
25. Song Y, Zhan P, Zhang Q, Liu X. Privileged scaffolds or promiscuous binders: a glance of pyrrolo[2, 1-f][1, 2, 4] triazines and related bridgehead nitrogen heterocycles in medicinal chemistry. Curr. Pharm. Design 19 (8), 1528-1548 (2013).